New Delhi, Nov. 27 -- Lords Mark India Ltd, a Mumbai-listed conglomerate offering diagnostics, medical technologies, renewable energy and paper, has acquired a controlling stake in a Bengaluru-based medical device maker to broaden its offerings in the diagnostics space.
The Mumbai-based company said it has acquired 85% stake in Renalyx Health Systems, marking its foray into renal diagnosis. While the financial terms of the transaction weren't disclosed, Lords Mark said its holding in Renalyx will increase to 92% by March 2026.
According to the company's stock exchange filing, the deal strengthens its capabilities in AI-enabled diagnostic devices and expands its presence in renal healthcare.
Post-transaction, Renalyx will function as the company's research and development (R&D) arm, supporting the development of medical technologies targeting chronic kidney disease (CKD) and related renal care solutions.
Renalyx Health Systems develops sustained low-efficiency dialysis machines (SLED) under the brand "Renalyx". Its AI-powered smart hemodialysis machine offers remote monitoring, clinical connectivity, real-time data access, and supports telenephrology platforms, aimed at enhancing patient safety and care quality. SLED is often used for patients with acute kidney injury (AKI), a sudden decrease in kidney function.
Lords Mark said the dialysis machine will be manufactured in collaboration with Bharat Electronics, following the receipt of a manufacturing licence.
Founded in 1998, Lords Mark started as a paper trading company and has since diversified into diagnostics, medical technologies, renewable energy and paper. Its footprint extends across 300 distributors in 22 states.
The company's healthcare arm, LordsMed, offers in-vitro diagnostics (IVD), medical devices, genome testing, surgical products, AI-based monitoring solutions and remote care technologies.
Published by HT Digital Content Services with permission from VC Circle.